PRA Health Sciences, Inc. (NASDAQ:PRAH)‘s stock had its “buy” rating restated by Jefferies Group in a research report issued to clients and investors on Saturday. They currently have a $63.00 price target on the stock. Jefferies Group’s target price would suggest a potential upside of 9.39% from the company’s previous close.

Several other research analysts also recently commented on the stock. TheStreet raised shares of PRA Health Sciences from a “hold” rating to a “buy” rating in a research note on Monday, November 14th. Citigroup Inc. lifted their price target on shares of PRA Health Sciences from $55.00 to $66.00 and gave the company a “buy” rating in a report on Thursday, September 22nd. Zacks Investment Research cut shares of PRA Health Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, November 9th. Credit Suisse Group reiterated a “hold” rating and issued a $50.00 price target on shares of PRA Health Sciences in a report on Thursday, November 3rd. Finally, KeyCorp reiterated a “buy” rating on shares of PRA Health Sciences in a report on Friday, November 4th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $56.71.

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

PRA Health Sciences (NASDAQ:PRAH) opened at 57.59 on Friday. PRA Health Sciences has a 12-month low of $35.60 and a 12-month high of $60.96. The firm’s 50-day moving average is $54.72 and its 200 day moving average is $51.48. The firm has a market cap of $3.54 billion, a P/E ratio of 44.71 and a beta of 0.53.

PRA Health Sciences (NASDAQ:PRAH) last issued its earnings results on Wednesday, November 2nd. The company reported $0.64 EPS for the quarter, hitting the consensus estimate of $0.64. PRA Health Sciences had a net margin of 4.86% and a return on equity of 21.25%. The company had revenue of $399.80 million for the quarter, compared to the consensus estimate of $394.87 million. During the same period in the previous year, the firm earned $0.52 earnings per share. The firm’s revenue for the quarter was up 15.9% on a year-over-year basis. Equities analysts forecast that PRA Health Sciences will post $2.46 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Jefferies Group Reaffirms “Buy” Rating for PRA Health Sciences, Inc. (PRAH)” was posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another website, it was stolen and republished in violation of United States & international trademark & copyright laws. The original version of this article can be viewed at http://www.dailypolitical.com/2017/01/14/jefferies-group-reaffirms-buy-rating-for-pra-health-sciences-inc-prah.html.

Several hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. boosted its stake in shares of PRA Health Sciences by 9,368.8% in the second quarter. JPMorgan Chase & Co. now owns 91,374 shares of the company’s stock worth $3,815,000 after buying an additional 90,409 shares during the period. State Board of Administration of Florida Retirement System boosted its stake in shares of PRA Health Sciences by 30.7% in the second quarter. State Board of Administration of Florida Retirement System now owns 12,846 shares of the company’s stock worth $536,000 after buying an additional 3,020 shares during the period. California Public Employees Retirement System boosted its stake in shares of PRA Health Sciences by 22.6% in the second quarter. California Public Employees Retirement System now owns 15,200 shares of the company’s stock worth $635,000 after buying an additional 2,800 shares during the period. Swiss National Bank boosted its stake in shares of PRA Health Sciences by 20.7% in the second quarter. Swiss National Bank now owns 54,258 shares of the company’s stock worth $2,266,000 after buying an additional 9,318 shares during the period. Finally, Bank of New York Mellon Corp boosted its stake in shares of PRA Health Sciences by 23.6% in the second quarter. Bank of New York Mellon Corp now owns 173,821 shares of the company’s stock worth $7,260,000 after buying an additional 33,229 shares during the period. Hedge funds and other institutional investors own 99.80% of the company’s stock.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization (CRO). The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

5 Day Chart for NASDAQ:PRAH

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.